Page last updated: 2024-11-07

rishirilide b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

rishirilide B: alpha-macroglobulin inhibitor from Streptomyces rishiriensis; structure given in first source; RN given refers to (1alpha,2beta,3alpha)-(+)-isomer; alpha macroglobulin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9976530
CHEMBL ID4169587
MeSH IDM0127934

Synonyms (8)

Synonym
rishirilide b
bdbm50366668
chembl4169587 ,
(1r,2r,3r)-1,2,8-trihydroxy-3-methyl-1-(3-methylbutyl)-4-oxo-3h-anthracene-2-carboxylic acid
DTXSID301108030
322728-38-1
rel-(1r,2r,3r)-1,2,3,4-tetrahydro-1,2,8-trihydroxy-3-methyl-1-(3-methylbutyl)-4-oxo-2-anthracenecarboxylic acid
AKOS040734074
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1356094Inhibition of glutathione S-transferase (unknown origin)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Biosynthetic Baeyer-Villiger Chemistry Enables Access to Two Anthracene Scaffolds from a Single Gene Cluster in Deep-Sea-Derived Streptomyces olivaceus SCSIO T05.
AID1356093Inhibition of alpha-2 macroglobulin (unknown origin)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Biosynthetic Baeyer-Villiger Chemistry Enables Access to Two Anthracene Scaffolds from a Single Gene Cluster in Deep-Sea-Derived Streptomyces olivaceus SCSIO T05.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's2 (18.18)18.2507
2000's4 (36.36)29.6817
2010's2 (18.18)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]